Definium Therapeutics (DFTX) Free Cash Flow (2019 - 2026)

Definium Therapeutics (DFTX) has 7 years of Free Cash Flow data on file, last reported at -$42.6 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$42.6 million, down 44.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$144.8 million (down 57.45% YoY), and the FY2025 annual result was -$131.6 million, down 66.26% from the prior year.
• Free Cash Flow improved to -$42.6 million in Q1 2026 per DFTX's latest filing, from -$43.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$9.3 million in Q3 2022 and troughed at -$43.0 million in Q4 2025.
• A 5-year average of -$21.6 million and a median of -$17.2 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 44.6% in 2022, then sank 78.83% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$12.8 million in 2022, then sank by 60.04% to -$20.6 million in 2023, then retreated by 23.28% to -$25.4 million in 2024, then sank by 69.52% to -$43.0 million in 2025, then grew by 0.8% to -$42.6 million in 2026.
• Business Quant data shows DFTX's Free Cash Flow at -$42.6 million in Q1 2026, -$43.0 million in Q4 2025, and -$29.6 million in Q3 2025.